JOSEPH MASCARO: Open Payments
NPI 1841834710 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$817 in 35 payments from 11 companies in 2025. Trend: 2023 $839 · 2024 $688 · 2025 $817
Food & beverage: $817
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $249 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $149 |
| Alnylam Pharmaceuticals Inc. | 5 | $107 |
| Amgen Inc. | 3 | $74 |
| E.R. Squibb & Sons, L.L.C. | 3 | $56 |
| United Therapeutics Corporation | 2 | $49 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| SCPHARMACEUTICALS INC. | 1 | $31 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
Products named: Wegovy, JARDIANCE, ONPATTRO, REPATHA, CAMZYOS, Tyvaso, FARXIGA, Ozempic.
Industry payments across PA — which companies pay providers there.
